Epkinly (epcoritamab-bysp)

P2, N=43, Not yet recruiting, City of Hope Medical Center

P2, N=33, Suspended, City of Hope Medical Center | Recruiting --> Suspended

This review focused on 4 CD20 × CD3 BsAbs, as well as surovatamig, a CD19 × CD3 BsAb currently under investigation that has demonstrated promising efficacy against relapsed/refractory B-cell lymphomas. All 4 CD20 × CD3 BsAbs are approved as third-line and beyond therapies: mosunetuzumab for follicular lymphoma (FL), glofitamab for diffuse large B-cell lymphoma (DLBCL), and epcoritamab and odronextamab for both FL and DLBCL (the latter in European Union only)...Multiple studies are currently evaluating these agents in both the relapsed/refractory and frontline settings, either as monotherapy or in combination with other agents. This review summarizes the efficacy and safety of each agent across B-cell lymphoma subtypes, along with their dosing schedules and CRS mitigation strategies.

P2, N=111, Active, not recruiting, Genmab | Trial completion date: Jul 2027 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026

P1/2, N=543, Active, not recruiting, Genmab | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2028 --> Sep 2027

P1/2, N=424, Recruiting, Genmab | Trial completion date: Aug 2029 --> Apr 2028 | Trial primary completion date: Jun 2029 --> Feb 2028

P2, N=22, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting

BsAbs targeting CD20/CD3, such as epcoritamab, glofitamab, mosunetuzumab, and odronextamab, are rapidly progressing toward widespread clinical application. Although monotherapy remains the standard approach, clinical trials are exploring earlier-line use and combination strategies to further enhance outcomes. Particular attention is given to predictive biomarkers of response and mechanisms of resistance, including target antigen loss, tumor histology, prior therapies, intratumoral and peripheral T-cell status, and the emerging role of minimal residual disease monitoring.

P2, N=26, Recruiting, University of Miami | Not yet recruiting --> Recruiting

P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting

P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center

IEC-HS is a rare but potentially fatal complication. Our disproportionality analysis identifies significant reporting signals for tisa-cel and cilta-cel. The high absolute number of cases observed for products like axi-cel appears to reflect high utilization rather than a disproportionate risk, underscoring the necessity of using statistical signal detection methods when interpreting spontaneous reports.